28 related articles for article (PubMed ID: 23544541)
1. Prediction and Preparation of Coamorphous Phases of a Bislactam.
Chambers LI; Musa OM; Steed JW
Mol Pharm; 2022 Jul; 19(7):2651-2661. PubMed ID: 35730408
[TBL] [Abstract][Full Text] [Related]
2. Influence of Aqueous Solubility-Enhancing Excipients on the Microstructural Characteristics of Furosemide-Loaded Electrospun Nanofibers.
Kovács A; Kazsoki A; Démuth B; Szirányi B; Madarász J; Süvegh K; Zelkó R
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32340196
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Aceclofenac Proniosomes by Using Different Carriers, Part 1: Development and Characterization.
Sammour RMF; Taher M; Chatterjee B; Shahiwala A; Mahmood S
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31323799
[TBL] [Abstract][Full Text] [Related]
4. Preformulation Studies of Furosemide-Loaded Electrospun Nanofibrous Systems for Buccal Administration.
Kovács A; Démuth B; Meskó A; Zelkó R
Polymers (Basel); 2017 Nov; 9(12):. PubMed ID: 30965943
[TBL] [Abstract][Full Text] [Related]
5. Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.
Gurturk Z; Tezcaner A; Dalgic AD; Korkmaz S; Keskin D
Medchemcomm; 2017 Jun; 8(6):1337-1345. PubMed ID: 30108846
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.
Radicioni M; Castiglioni C; Giori A; Cupone I; Frangione V; Rovati S
Drug Des Devel Ther; 2017; 11():1183-1192. PubMed ID: 28442892
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of various solubility enhancement strategies for furosemide.
Murtaza G; Khan SA; Najam-ul-Haq M; Hussain I
Pak J Pharm Sci; 2014 Jul; 27(4):963-73. PubMed ID: 25015467
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling and electron diffraction of polysaccharides.
Pérez S
Methods Enzymol; 1991; 203():510-56. PubMed ID: 1762570
[No Abstract] [Full Text] [Related]
9. Improving furosemide polymorphs properties through supramolecular complexes of β-cyclodextrin.
Garnero C; Chattah AK; Longhi M
J Pharm Biomed Anal; 2014 Jul; 95():139-45. PubMed ID: 24667568
[TBL] [Abstract][Full Text] [Related]
10. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
11. Stability of furosemide polymorphs and the effects of complex formation with β-cyclodextrin and maltodextrin.
Garnero C; Chattah AK; Longhi M
Carbohydr Polym; 2016 Nov; 152():598-604. PubMed ID: 27516309
[TBL] [Abstract][Full Text] [Related]
12. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery.
Jug M; Maestrelli F; Bragagni M; Mura P
J Pharm Biomed Anal; 2010 May; 52(1):9-18. PubMed ID: 20004541
[TBL] [Abstract][Full Text] [Related]
13. insights into novel supramolecular complexes of two solid forms of norfloxacin and β-cyclodextrin.
Chattah AK; Mroue KH; Pfund LY; Ramamoorthy A; Longhi MR; Garnero C
J Pharm Sci; 2013 Oct; 102(10):3717-24. PubMed ID: 23904189
[TBL] [Abstract][Full Text] [Related]
14. Supramolecular complexes of maltodextrin and furosemide polymorphs: a new approach for delivery systems.
Garnero C; Chattah AK; Longhi M
Carbohydr Polym; 2013 Apr; 94(1):292-300. PubMed ID: 23544541
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
